Skip to main content
Top
Published in: Pituitary 3/2012

01-09-2012

Serum adipokines and low density lipoprotein subfraction profile in hypopituitary patients with growth hormone deficiency

Authors: Serpil Salman, Ayse Kubat Uzum, Aysegul Telci, Faruk Alagol, Nese Colak Ozbey

Published in: Pituitary | Issue 3/2012

Login to get access

Abstract

The aim was to evaluate the concentrations of lipid subfractions in relation to adipokines and metabolic parameters in adult growth hormone (GH)-deficient hypopituitary patients on conventional replacement therapy. The study included 21 GH deficient-hypopituitary patients (age: 36.0 ± 15.1 years, male/female: 7/14) on conventional replacement therapy other than GH and 20 comparable controls (age: 37.3 ± 14.0 years, male/female: 6/14). Lipid subfractions (Lipoprint system), serum adipokine (leptin, adiponectin, resistin) concentrations, body composition, a surrogate marker for insulin resistance (HOMA) and conventional lipid profile were evaluated. No statistically significant difference was found with respect to HOMA, adipokine concentrations and anthropometric parameters between patients and controls except for significantly increased waist-to-hip ratio in hypopituitary group. Total and LDL cholesterol concentrations were significantly higher in the patients. LDL particle size (268.88 ± 3.16 vs. 271.31 ± 3.11 Å, P = 0.151) and small-dense LDL subfraction did not differ significantly. According to logistic regression analysis, triglyceride concentrations ≥1.69 mmol/L was the sole parameter significantly and independently predicted small (<268 Å) LDL particle size (P = 0.019) in the whole group. Increased triglyceride concentrations affect LDL particle size in GH-deficient hypopituitary patients. Small dense LDL seems not directly contribute to atherogenic potential in hypopituitarism.
Literature
1.
go back to reference Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288PubMedCrossRef Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288PubMedCrossRef
2.
go back to reference Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Steward PM (2001) West Midlands Prospective Hypopituitary Study Group: association between premature mortality and hypopituitarism. Lancet 357:425–443PubMedCrossRef Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Steward PM (2001) West Midlands Prospective Hypopituitary Study Group: association between premature mortality and hypopituitarism. Lancet 357:425–443PubMedCrossRef
3.
go back to reference Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmonds D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorner M (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 83:382–395PubMedCrossRef Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmonds D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorner M (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 83:382–395PubMedCrossRef
4.
go back to reference Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, Wilton P, Koltowska-Haggstrom M (2006) Determinants of cardiovascular risk in 2,589 hypopituitary GH-deficient adults—a KIMS database analysis. Eur J Endocrinol 255:79–90CrossRef Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, Wilton P, Koltowska-Haggstrom M (2006) Determinants of cardiovascular risk in 2,589 hypopituitary GH-deficient adults—a KIMS database analysis. Eur J Endocrinol 255:79–90CrossRef
5.
go back to reference Rabe K, Lehrke M, Parhofer KG, Broedl UC (2008) Adipokines and insulin resistance. Mol Med 14:741–751PubMedCrossRef Rabe K, Lehrke M, Parhofer KG, Broedl UC (2008) Adipokines and insulin resistance. Mol Med 14:741–751PubMedCrossRef
6.
go back to reference Bülow B, Ahrén B, Erfurth EM (2001) Increased leptin and tumor necrosis factor α per unit fat mass in hypopituitary women without growth hormone treatment. Eur J Endocrinol 146:737–742CrossRef Bülow B, Ahrén B, Erfurth EM (2001) Increased leptin and tumor necrosis factor α per unit fat mass in hypopituitary women without growth hormone treatment. Eur J Endocrinol 146:737–742CrossRef
7.
go back to reference Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939PubMedCrossRef Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939PubMedCrossRef
8.
go back to reference Ukropec J, Penesova A, Skopkova M, Pura M, Vicek M, Radikova Z, Imrich R, Ukropcova B, Tajtakova M, Koska J, Zorad S, Belan V, Vanuga P, Payer J, Eckel J, Klimes I, Gasperikova D (2008) Adipokine protein expression pattern in growth hormone deficiency predisposes to increased fat cell size and whole body metabolic derangements. J Clin Endocrinol Metab 93:2255–2262PubMedCrossRef Ukropec J, Penesova A, Skopkova M, Pura M, Vicek M, Radikova Z, Imrich R, Ukropcova B, Tajtakova M, Koska J, Zorad S, Belan V, Vanuga P, Payer J, Eckel J, Klimes I, Gasperikova D (2008) Adipokine protein expression pattern in growth hormone deficiency predisposes to increased fat cell size and whole body metabolic derangements. J Clin Endocrinol Metab 93:2255–2262PubMedCrossRef
9.
go back to reference Rizzo M, Berneis K (2006) Low-density lipoprotein size and cardiovascular risk assessment. QJM 99:1–14PubMedCrossRef Rizzo M, Berneis K (2006) Low-density lipoprotein size and cardiovascular risk assessment. QJM 99:1–14PubMedCrossRef
10.
go back to reference O’Neal D, Hew FL, Sikaris K, Ward G, Alford F, Best JD (1996) Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy. J Clin Endocrinol Metab 81:2448–2454PubMedCrossRef O’Neal D, Hew FL, Sikaris K, Ward G, Alford F, Best JD (1996) Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy. J Clin Endocrinol Metab 81:2448–2454PubMedCrossRef
11.
go back to reference Rizzo M, Trepp R, Berneis K, Christ ER (2007) Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. Eur J Endocrinol 146:361–367CrossRef Rizzo M, Trepp R, Berneis K, Christ ER (2007) Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. Eur J Endocrinol 146:361–367CrossRef
12.
go back to reference Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ, HyposCCS Advisory Board, U.S. HypoCCS Study Group (2002) Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 87:477–485PubMedCrossRef Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ, HyposCCS Advisory Board, U.S. HypoCCS Study Group (2002) Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 87:477–485PubMedCrossRef
13.
go back to reference Leong KS, Walker AB, Martin I, Wile D, Wilding J, MacFarlane IA (2001) An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clin Endocrinol 54:463–468CrossRef Leong KS, Walker AB, Martin I, Wile D, Wilding J, MacFarlane IA (2001) An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clin Endocrinol 54:463–468CrossRef
14.
go back to reference Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef
15.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
16.
go back to reference Rizzo M, Trepp R, Berneis K, Christ ER (2008) Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency. Growth Horm IGF Res 18:264–266PubMedCrossRef Rizzo M, Trepp R, Berneis K, Christ ER (2008) Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency. Growth Horm IGF Res 18:264–266PubMedCrossRef
17.
go back to reference Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479PubMedCrossRef Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479PubMedCrossRef
18.
go back to reference Giavoli C, Cappiello V, Corbetta S, Ronchi CL, Morpurgo PS, Ferrante E, Beck-Peccoz P, Spada A (2004) Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clin Endocrinol 61:81–87CrossRef Giavoli C, Cappiello V, Corbetta S, Ronchi CL, Morpurgo PS, Ferrante E, Beck-Peccoz P, Spada A (2004) Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clin Endocrinol 61:81–87CrossRef
19.
go back to reference Joaquin C, Aguilera E, Granada ML, Pastor MC, Salinas I, Alonso N, Sanmarti A (2008) Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol 158:483–490PubMedCrossRef Joaquin C, Aguilera E, Granada ML, Pastor MC, Salinas I, Alonso N, Sanmarti A (2008) Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol 158:483–490PubMedCrossRef
Metadata
Title
Serum adipokines and low density lipoprotein subfraction profile in hypopituitary patients with growth hormone deficiency
Authors
Serpil Salman
Ayse Kubat Uzum
Aysegul Telci
Faruk Alagol
Nese Colak Ozbey
Publication date
01-09-2012
Publisher
Springer US
Published in
Pituitary / Issue 3/2012
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-011-0332-1

Other articles of this Issue 3/2012

Pituitary 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.